Ganesan RMSS
Hashimoto's thyroiditis Hashimoto's thyroiditis is one of the more commonly discussed autoimmune conditions in the context of GLP-1 medications, partly because thyroid function monitoring is already recommended for tirzepatide users due to the medication boxed warning about medullary thyroid carcinoma risk
Commonly reported effects include nausea, vomiting, diarrhea, constipation, stomach discomfort, reduced appetite, headache, and fatigue
While obesity itself significantly increases venous thromboembolism risk, current evidence shows these injections do not add to that risk and may actually improve cardiovascular health through weight reduction
Body fat percentage is going down
The company has, however, faced some significant challenges